文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.

作者信息

Foster Matthew C, Savoldo Barbara, Lau Winnie, Rubinos Clio, Grover Natalie, Armistead Paul, Coghill James, Hagan Robert S, Morrison Kaitlin, Buchanan Faith Brianne, Cheng Catherine, Laing Spencer, Ivanova Anastasia, West John, Foster Aaron, Serody Jonathan, Dotti Gianpietro

机构信息

Department of Medicine, School of Medicine.

Lineberger Comprehensive Cancer Center.

出版信息

Blood. 2021 Jun 10;137(23):3306-3309. doi: 10.1182/blood.2021010784.

DOI:10.1182/blood.2021010784
PMID:33624095
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8351894/
Abstract
摘要

相似文献

[1]
Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.

Blood. 2021-6-10

[2]
Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.

Ann Med. 2024-12

[3]
Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL.

Cancer Immunol Immunother. 2021-7

[4]
Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy Ameliorating Endothelial Activation.

Front Immunol. 2021

[5]
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.

J Hematol Oncol. 2020-4-3

[6]
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.

Blood Adv. 2019-11-26

[7]
Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.

Clin Lymphoma Myeloma Leuk. 2021-4

[8]
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

Cancer Discov. 2018-6-7

[9]
Late Events After CD-19 CAR-T Treatment.

Biol Blood Marrow Transplant. 2020-1

[10]
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.

Am J Hematol. 2021-6-1

引用本文的文献

[1]
B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer.

J Immunother Cancer. 2025-5-26

[2]
Gene regulation technologies for gene and cell therapy.

Mol Ther. 2025-5-7

[3]
Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy.

Cells. 2025-2-20

[4]
The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials.

Front Oncol. 2024-9-27

[5]
ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights.

Front Immunol. 2024

[6]
Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy.

Acta Pharm Sin B. 2024-8

[7]
Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using a Quantum pBac-based CAR-T engineering system.

PLoS One. 2024

[8]
T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting.

Mol Ther. 2024-9-4

[9]
Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers.

Exp Hematol Oncol. 2024-7-26

[10]
Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control.

Blood Cancer J. 2024-6-18

本文引用的文献

[1]
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

N Engl J Med. 2020-4-2

[2]
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Biol Blood Marrow Transplant. 2018-12-25

[3]
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Lancet Oncol. 2018-12-2

[4]
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

N Engl J Med. 2018-12-1

[5]
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

Cancer Discov. 2018-6-7

[6]
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

N Engl J Med. 2018-2-1

[7]
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

Cancer Discov. 2017-10-12

[8]
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Nat Rev Clin Oncol. 2017-9-19

[9]
Amid FDA Approval Filings, Another CAR-T Therapy Patient Death.

JAMA. 2017-6-13

[10]
Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.

Mol Ther. 2017-3-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索